despite the less-than-encouraging news, dr. adam kassam, president of the oma, reminded attendees that significant progress has been made over the past 21 months, saying that there is reason to be positive moving forward.
“w
e are fundamentally in a different place than we were a year ago,”
he said.
“we have the vaccine, we have therapeutics, we have a better understanding of the disease and its transmission.”
the case for third doses and evaluating new booster shots
preliminary data
from the first three weeks of the omicron variant’s progression in south america suggest that while the double course of pfizer-biontech only provides 33 per cent protection against contracting covid-19 — down from 80 per cent in previous variants — it still provides approximately 70 per cent protection against hospitalization during the course of a covid illness. (two shots of pfizer-biontech gives 93 per cent protection against hospitalization
due to delta
.)
while a 23 per cent decrease in protection against hospitalization doesn’t seem like much, the drop coupled with an increase in transmission, could still put significant strain on the healthcare system, prompting concern.
allison mcgeer, is a professor of laboratory medicine and pathobiology at the dalla lana school of public health and an infectious disease specialist. (2002)
mcgeer says that while development of a booster vaccine for the new variant has an approximately four-month time frame, third doses of the original mrna vaccine do provide substantial protection against omicron.
early research
by the uk health security agency suggests that a third shot of pfizer-biontech boosts protection against developing symptoms from omicron with “moderate to high effectiveness.” however, the researchers have cautioned that these preliminary results are based on a smaller sample set that may change as the wave progresses.